The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previous...
Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report this very positive and important development for mdxhealth. The quality ...
The Centers for Disease Control and Prevention today reported 26.7 percent of people with autism spectrum disorder have "profound autism". It is the first ...
A.Menarini Diagnostics S.r.l. (Menarini) is pleased to announce an exclusive distribution agreement for the AFIAS-10 System and IGRA-TB Assay (among others...
Juntendo University, Sysmex Corporation, and ThinkCyte K.K. have announced a collaborative research partnership to advance the early detection and treatmen...
"Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's C...
A preclinical study using stem cells to produce progenitor photoreceptor cells—light-detecting cells found in the eye—and then transplant...
Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researcher...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer ...
Daon, the Digital Identity Trust company, is expanding its identity proofing and authentication solutions to the healthcare industry to enable organization...
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the init...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation ...
OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligen...
Cold Spring Harbor Laboratory Professor Adrian Krainer is best known for his groundbreaking research on antisense oligonucleotides (ASOs)—m...
© 2024 Biopharma Boardroom. All Rights Reserved.
